Clinical trial
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
NCT00497952 · Talaris Therapeutics Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00497952 |
|---|---|
| Title | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis |
| Official title | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis |
| Lead sponsor | Talaris Therapeutics Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Biological |
| Interventions | hematopoetic stem cell infusion |
| Enrollment | 0 |
| Start date | Jul 1, 2007 |
| Primary completion | Dec 1, 2024 |
| Completion | Dec 1, 2024 |
| First posted | Jul 9, 2007 |
| Last update posted | Oct 12, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: